SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine launched an expanded access program (EAP) for bitopertin…

Disc Medicine Inc · PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET

Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.

  • EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
  • Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
  • Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
  • Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access